From The Washington Post:
Experimental therapies with radically different approaches are stirring a wave of optimism that survival rates could substantially improve for pancreatic cancer, one of the most stubbornly lethal forms of the disease. Giving doctors and patients more options to standard chemotherapy would “increase shots on goal” and perhaps even make the dreaded diagnosis manageable over a number of years, according to experts.The furthest along and generating the most excitement is a pill developed by Revolution Medicines, which inhibits a protein that signals cancer cells to multiply and drives tumor formation and growth. Phase 3 clinical trial results announced this month showed patients treated with the new drug, called daraxonrasib, had median survival of 13.2 months compared to 6.7 months for people receiving chemotherapy.
…“We have moved from famine to feast in this disease,” said Shubham Pant, an oncologist who specializes in treating gastrointestinal cancers at the University of Texas MD Anderson Cancer Center. He spoke in San Diego on Tuesday at an American Association for Cancer Research conference session entitled, “Turning the tide in the fight against pancreatic cancer.”
More here.
Enjoying the content on 3QD? Help keep us going by donating now.